CINECA IRIS Institutional Research Information System

ALBERA, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.346
EU - Europa 3.512
AS - Asia 2.003
SA - Sud America 210
OC - Oceania 162
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.134
CN - Cina 932
IT - Italia 787
GB - Regno Unito 474
IE - Irlanda 414
FR - Francia 349
SE - Svezia 312
DE - Germania 253
FI - Finlandia 217
SG - Singapore 196
JP - Giappone 188
CA - Canada 179
KR - Corea 169
UA - Ucraina 158
BR - Brasile 137
AU - Australia 131
IN - India 119
VN - Vietnam 103
TR - Turchia 96
ES - Italia 80
NL - Olanda 79
PL - Polonia 66
BE - Belgio 61
PT - Portogallo 48
CH - Svizzera 40
TW - Taiwan 35
HK - Hong Kong 34
NZ - Nuova Zelanda 29
AT - Austria 26
MX - Messico 25
DK - Danimarca 24
RU - Federazione Russa 23
PK - Pakistan 22
RO - Romania 21
ID - Indonesia 20
AR - Argentina 18
CL - Cile 18
CO - Colombia 18
GR - Grecia 17
IL - Israele 17
TH - Thailandia 17
MY - Malesia 16
NO - Norvegia 14
PE - Perù 13
IR - Iran 11
ZA - Sudafrica 11
HU - Ungheria 10
PH - Filippine 10
EU - Europa 9
EG - Egitto 7
LT - Lituania 7
CZ - Repubblica Ceca 6
BG - Bulgaria 5
BY - Bielorussia 5
HR - Croazia 5
PR - Porto Rico 5
TN - Tunisia 5
MU - Mauritius 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
LB - Libano 3
UY - Uruguay 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
EC - Ecuador 2
FJ - Figi 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
SI - Slovenia 2
GH - Ghana 1
GT - Guatemala 1
IQ - Iraq 1
LK - Sri Lanka 1
MA - Marocco 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
RE - Reunion 1
RW - Ruanda 1
SC - Seychelles 1
SN - Senegal 1
UG - Uganda 1
UZ - Uzbekistan 1
Totale 11.278
Salva come PNG Salva come JPEG
Città #
Houston 956
Beijing 488
Chandler 416
Dublin 393
Fairfield 286
Ashburn 209
Hangzhou 190
Redwood City 188
Wilmington 172
Singapore 137
Seattle 135
Villeurbanne 134
Woodbridge 130
Medford 128
Torino 123
Ann Arbor 121
Princeton 114
Cambridge 90
Pisa 84
Milan 78
Jacksonville 77
Nyköping 74
Dong Ket 71
Dearborn 62
Duncan 57
Warsaw 55
Tokyo 54
Turin 53
London 52
Boston 48
Shanghai 43
Boardman 35
Ottawa 29
Toronto 28
Washington 27
New York 26
Istanbul 25
Paris 23
Norwalk 22
Verona 22
Los Angeles 21
Seoul 21
Lachine 20
San Diego 20
Sydney 18
Vienna 18
Nanjing 17
Santa Clara 17
São Paulo 17
Taipei 17
Brussels 16
Mumbai 16
Southend 16
Guangzhou 15
Menlo Park 15
Mountain View 15
Phoenix 15
Santiago 15
Ankara 14
Québec 14
Barcelona 13
Lima 13
Seongnam 13
Auckland 12
Chicago 12
Hobart 12
Chengdu 11
Delhi 11
Falls Church 11
Frankfurt am Main 11
Fremont 11
Helsinki 11
New Delhi 11
Rotterdam 11
Silver Spring 11
Atlanta 10
Bangkok 10
Denver 10
Hefei 10
Jakarta 10
Madrid 10
Nutley 10
Pittsburgh 10
San Jose 10
Zurich 10
Dallas 9
Detroit 9
Mannheim 9
Porto 9
Rome 9
Athens 8
Auburn Hills 8
Bengaluru 8
Berlin 8
Hong Kong 8
Manchester 8
Napoli 8
Oxnard 8
Padova 8
Philadelphia 8
Totale 6.191
Salva come PNG Salva come JPEG
Nome #
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. 2.677
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. 855
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. 578
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. 484
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. 379
Documento AIPO-SIMeR sulla fibrosi polmonare idiopatica 258
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. 250
Activated and memory alveolar T-lymphocytes in idiopathic eosinophilic pneumonia. 165
Relationship between circulating immune complexes, serum interferon and clinical features in sarcoidosis. 164
Eosinophils in eosinophilic pneumonia. 141
Evaluation of a novel tuberculosis complex-specific 34 kDa protein in the serological diagnosis of tuberculosis. 136
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial 130
Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers. 129
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. 123
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. 114
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points 109
Tachykinin activation of human alveolar macrophages in tobacco-smoke and in sarcoidosis: a phenotypical and functional study 105
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 103
Human renal angiomyolipoma cells of male and female origin can migrate and are influnced by microenvironmental factors 103
The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report 101
null 96
Risultati iniziali e prospettive future del Registro Piemontese delle Cardiopatie Congenite dell'Adulto 96
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier 94
Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. 93
The clinical use of BAL in patients with pulmonary infections. 85
Corso di malattie dell'apparato respiratorio 84
First report of the Italian register for diffuse infiltrative lung disorders(RIPID). 83
Clinical guidelines and indications for bronchoalveolar lavage (BAL): pulmonary malignancies. 83
Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. 80
Alveolar inflammation in pulmonary sarcoidosis: cells and mediators. 78
Tumor/Stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis 77
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 77
Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice 77
Awake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study 77
[Alveolar macrophage subpopulations and circulating monocytes. Immunophenotypic study in healthy non-smokers] 76
Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule. 73
[Evaluation of leukocyte migration inhibition (LIF) in patients with carcinoma of the lung before and after the use of levamisole in vitro] 71
[Diagnosis of tuberculosis today] 71
Lymphocyte subpopulations analysis in pleural fluid and peripheral blood in patients with lymphocytic pleural effusions. 70
Fibronectin levels in bronchoalveolar lavage fluid: a possible marker of sarcoidosis activity. 68
Three-dimensional demonstration of systemic blood supply to normal left basal segments 68
Analysis of survival in lung transplantation: Simple diagnostic tests in a new "SELeCT" Score used as prognostic tool. Results from a single center cohort study 68
[In vitro lymphocyte immunoreactivity in sarcoidosis patients. Stimulation with Kveim antigens] 67
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 67
Mediastinal pulmonary sarcoidosis: clinical study of 87 cases 66
[Sarcoidosis] 65
Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality? 63
First rigid bronchoscopy in COVID-19 pneumonia to treat a rare endobronchial tumor during extracorporeal membrane oxygenation 61
Sarcoid activity markers. 60
Broncholaveolar Lavage in Sarcoidosis 60
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. 60
Evaluation of immunomodulating effects of inhaled bacterial polyribosomal-Klebsiella pneumoniae proteoglycans complex on bronchoalveolar immune system in chronic bronchitis. 59
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials 59
Alveolar immune mediators in HIV-related pneumonia. Different role of IL-2 and IL-1 in inducing lung damage. 58
6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) 56
Fibrosi Polmonare 55
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 55
Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. 54
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. 54
Alveolar and circulating CD8+ lymphocyte subsets in pulmonary sarcoidosis 52
Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives 52
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. 51
Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis 50
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. 50
Uno studio placebo-controllo sull’uso dell’interferon gamma-1b in pazienti con fibrosi polmonare idiopatica Commento editoriale da N Engl J Med 2004;350:125-33 A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis RAGHU G, BROWN KK, BRADFORD WZ, STARKO K, NOBLE PW, SCHWARTZ DA, KING TE FOR THE IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP 49
Think before: a guide to early diagnosis of pulmonary hypertension in patients with connective tissue diseases and vice versa. 48
Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA 47
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis 45
Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes 45
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. 44
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) 44
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. 44
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials 43
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. 43
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications 42
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. 41
Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients 40
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. 39
SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience 39
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials 38
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 38
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 37
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. 37
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial 36
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 35
Progressive fibrosing interstitial lung diseases: A current perspective 35
Riociguat for the treatment of pulmonary arterial hypertension. 34
Where do we stand with IPF treatment? 33
Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair 33
Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85) 33
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis 32
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement 32
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial 32
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 31
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis 31
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study 31
Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. 30
Circulating biomarkers in pulmonary arterial hypertension: update and future direction. 30
null 29
Mode of Death in Patients with Pulmonary Arterial Hypertension 27
Totale 11.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.106
article - articoli 0
book - libri 0
conference - conferenze 836
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.942
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.163 0 76 108 199 195 812 186 118 145 131 122 71
2020/20211.363 103 66 124 93 108 109 100 93 150 103 105 209
2021/20221.360 85 89 100 103 80 70 67 103 83 97 225 258
2022/20231.808 163 100 64 168 197 436 185 107 166 39 99 84
2023/20241.082 118 144 85 63 85 98 57 80 22 91 101 138
2024/2025158 50 108 0 0 0 0 0 0 0 0 0 0
Totale 11.793